 Heart valve replacement options remain exceedingly limited for pediatric patients because they can not accommodate somatic growth. To overcome this shortcoming , heart valve tissue engineering using human bone<disease> marrow stem cells ( HBMSCs) has been considered a potential solution to the treatment of critical congenital valvular defects. The mechanical environments during